Form 8-K - Current report:
SEC Accession No. 0001493152-20-022628
Filing Date
2020-11-27
Accepted
2020-11-27 16:43:25
Documents
7
Period of Report
2020-11-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm 8-K 50727
2 ex1-1.htm EX-1.1 345624
3 ex3-1.htm EX-3.1 7461
4 ex4-1.htm EX-4.1 118266
5 ex4-2.htm EX-4. 103310
6 ex99-1.htm EX-99.1 12839
7 ex99-1_002.jpg GRAPHIC 6678
  Complete submission text file 0001493152-20-022628.txt   648876
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 201355601
SIC: 2834 Pharmaceutical Preparations